Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dibotermin alfa + Mastergraft** is a combination product used in orthopedic surgery to promote bone formation and healing. Dibotermin alfa is a recombinant human Bone Morphogenetic Protein-2 (rhBMP-2), a potent osteoinductive agent that stimulates mesenchymal stem cells to differentiate into bone-forming cells. Mastergraft consists of a family of synthetic bone graft substitutes, primarily composed of hydroxyapatite and tricalcium phosphate, which serve as a biocompatible osteoconductive scaffold facilitating new bone growth. This combination is used to enhance bone regeneration in spinal fusion, long bone fractures, and dental/maxillofacial surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibotermin alfa + Mastergraft.